You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 398 AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
398 AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy

 

Online download statistics by month:

Online download statistics by month: November 2020 to August 2025

AbstractFullPdf
Nov 2020243027
Dec 202021017
Jan 20213205
Feb 20213203
Mar 202198012
Apr 20215608
May 20211704
Jun 2021007
Jul 20210010
Aug 2021006
Sep 20210012
Oct 202148022
Nov 202177028
Dec 20213307
Jan 20223603
Feb 20221602
Mar 20224804
Apr 20224605
May 20224802
Jun 20224602
Jul 20224206
Aug 20225606
Sep 20223804
Oct 20223405
Nov 20227406
Dec 20223004
Jan 20232402
Feb 20234403
Mar 20236404
Apr 20233603
May 20235808
Jun 20232002
Jul 20234005
Aug 20233008
Sep 20233809
Oct 20232608
Nov 20233407
Dec 20237402
Jan 20241604
Feb 20241800
Mar 20243403
Apr 20241205
May 20244602
Jun 20243609
Jul 202446012
Aug 20245209
Sep 20244406
Oct 20243408
Nov 20245008
Dec 20242604
Jan 202548012
Feb 202510012
Mar 20250010
Apr 2025007
May 2025008
Jun 2025006
Aug 2025100
Total21320403